Precipio announces preliminary unaudited q2-2021 revenues of $2.3m

Increase of 65% yoy, and 29% from q1-2021 due to strong pathology growth and hemescreen increase of 65% yoy, and 29% from q1-2021 due to strong pathology growth and hemescreen

PRPO Ratings Summary

PRPO Quant Ranking